Evidence map›Paper›PMID 35335266›Full record

ReviewMolecules (Basel, Switzerland)2022

An Insight into Antihyperlipidemic Effects of Polysaccharides from Natural Resources.

Yong-Shuai Jing, Yun-Feng Ma, Fei-Bing Pan, Ming-Song Li, Yu-Guang Zheng, Lan-Fang Wu, Dan-Shen Zhang

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Bioactives in Food-As-Medicine for Special Medical Purposes.Advances in nutrition (Bethesda, Md.) · 2025
    Review
  5. Review
  6. Review
  7. Effect ofFoods (Basel, Switzerland) · 2025
    Article
  8. AcetylatedFrontiers in oncology · 2025
    Article
  9. Review
  10. Heliyon · 2024
    Review
  11. Hypolipidemic and Antithrombotic Effect of 6'-Molecules (Basel, Switzerland) · 2024
    Article
  12. Molecules (Basel, Switzerland) · 2024
    Article
  13. Article
  14. Molecules (Basel, Switzerland) · 2022
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yong-Shuai JingCollege of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, 26 Yuxiang Street, Shijiazhuang 050018, China.ORCID 0000-0002-9362-4554
Yun-Feng MaCollege of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, 26 Yuxiang Street, Shijiazhuang 050018, China.
Fei-Bing PanHuachuang Institute of Areca Research-Hainan, Haikou 570125, China.
Ming-Song LiCollege of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, 26 Yuxiang Street, Shijiazhuang 050018, China.
Yu-Guang ZhengCollege of Pharmacy, Hebei University of Chinese Medicine, 3 Xingyuan Road, Shijiazhuang 050200, China.
Lan-Fang WuCollege of Pharmacy, Hebei University of Chinese Medicine, 3 Xingyuan Road, Shijiazhuang 050200, China.
Dan-Shen ZhangCollege of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, 26 Yuxiang Street, Shijiazhuang 050018, China.
Hebei University of Science and Technology · CNHebei University of Chinese Medicine · CN

Funding

Fund of Dean of Huachuang Institute of Areca Research-Hainan HCBL2020YZ-012the S & T Program of Hebei H2021208007
6 · The paper itself

Abstract

Hyperlipidemia is a chronic metabolic disease caused by the abnormal metabolism of lipoproteins in the human body. Its main hazard is to accelerate systemic atherosclerosis, which causes cerebrovascular diseases such as coronary heart disease and thrombosis. At the same time, although the current hypolipidemic drugs have a certain therapeutic effect, they have side effects such as liver damage and digestive tract discomfort. Many kinds of polysaccharides from natural resources possess therapeutic effects on hyperlipidemia but still lack a comprehensive understanding. In this paper, the research progress of natural polysaccharides on reducing blood lipids in recent years is reviewed. The pharmacological mechanisms and targets of natural polysaccharides are mainly introduced. The relationship between structure and hypolipidemic activity is also discussed in detail. This review will help to understand the value of polysaccharides in lowering blood lipids and provide guidance for the development and clinical application of new hypolipidemic drugs.

Indexed as

HyperlipidemiasHypolipidemic AgentsHumansNatural ResourcesPolysaccharidesHypolipidemic AgentsPolysaccharideshyperlipidemiamechanismspolysaccharidesstructure–activity relationship

Identifiers

PMID35335266
PMCPMC8952498
OpenAlexW4220871763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.